HOME >> BIOLOGY >> NEWS
Sunlight converts common anti-bacterial agent to dioxin

MINNEAPOLIS / ST. PAUL--Sunlight can convert triclosan, a common disinfectant used in anti-bacterial soaps, into a form of dioxin, and this process may produce some of the dioxin found in the environment, according to research at the University of Minnesota. The researchers said that although the dioxin was a relatively benign form, treating wastewater with chlorine could possibly lead to the production of a much more toxic species of dioxin. The study is in press in the Journal of Photochemistry and Photobiology A: Chemistry.

It had already been known that triclosan could be converted to dioxin in the laboratory, and it was also known that sunlight causes triclosan to degrade in the environment. But it had not been known that the natural degradation resulted in dioxin, said researchers Kristopher McNeill, an assistant professor of chemistry, and William Arnold, assistant professor of civil engineering. They discovered that the reaction could occur in Mississippi River water exposed to ultraviolet light.

"This form of dioxin is at least 150,000 times less toxic than the most dangerous form," said McNeill. "But repeated exposure to chlorine, perhaps in water treatment facilities, could chlorinate triclosan. After chlorinated triclosan is discharged from the facility, sunlight could convert it into more toxic dioxins. Such a process could be a source of highly toxic dioxin in the environment."

"This study also shows that the disappearance of a pollutant such as triclosan doesn't necessarily mean an enviromental threat has been removed," said Arnold. "It may just have been converted into another threat."

The researchers began their study after reading numerous environmental studies that reported the presence of pharmaceutical compounds in surface waters around the nation. McNeill and Arnold decided that the logical next step was to examine the natural processes that led to the loss of such materials in the environment. Last year, the U.
'"/>

Contact: Deane Morrison
morri029@umn.edu
612-624-2346
University of Minnesota
14-Apr-2003


Page: 1 2

Related biology news :

1. Sunlight, PCB exposure enhance skin cancer chances
2. How Nature Harvests Sunlight
3. Researchers discover new oceanic bacterial photopigment that converts light into biochemical energy
4. New process converts municipal waste into commodities and fuel
5. Most recent common ancestor of all living humans surprisingly recent
6. Hidden diversity: DNA barcoding reveals a common butterfly is actually 10 different species
7. European common frog found to use novel mating strategy
8. Genetic clues found for common congenital brain disorder
9. Stanford researchers findings may shed light on common, deadly birth defect
10. U-M scientists find common virus in human prostate tissue
11. Scientists suggest framework for epigenetics in common disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Sunlight converts common anti bacterial agent dioxin

(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... Ralco is ... Center at the Lyon County Fair to be held August 5-9 in Marshall. The ... where their meals come from and how agriculture impacts their daily lives. This unique ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
Cached News: